Subjects eligible for this clinical trial include patients who have been on Coumadin  (warfarin) to treat a blood clot in the legs or lungs that developed in the past 6-18 months. This study is evaluating an investigational medicine to determine its efficacy in preventing recurrent blood clots. Unlike Coumadin (warfarin), this drug is not affected by food and does not require repeated blood testing to measure its safety or efficacy. The study will last 6-12 months. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

A novel, oral anticoagulant is being evaluated in persons with a recent Acute Coronary Syndrome / Heart Attack. This study is expected to last for an average of 28 months. The study medication will administered in addition to  the standard of care for this condition in order to determine if it prevents cardiovasclar events better than the standard of care. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

This is a clinical trial comparing the safety and efficacy of generic Fluorouracil cream to the brand name product, Efudex cream. It is a six week study with two weeks of treatment followed by four weeks post treatment. Eligible participants will receive skin exams and study medication at no cost.

This study is evaluating the whether a novel cholesterol medication decreases the risk of cardiovascular events in persons with a recent acute coronary syndrome. Persons who have recently been hospitalized with an Acute Coronary Syndrome / Heart Attack may be eligible to participate in this 2-year study. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

The study will evaluate the ability of an investigational drug to prevent gouty attacks in persons at risk of experiencing such attacks. The study drug is administered subcutaneously once-per-week. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

A novel blood thinner is being compared with Coumadin (warfarin) in this two year study which will compare the risk of stroke/TIA (mini-stroke)/systemic embolism in persons with atrial fibrillation and risk factors for stroke.  Unlike Coumadin (warfarin), this drug is not affected by food and does not require repeated blood testing to measure its safety or efficacy. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

Patients with ulcerative colitis are eligible to participate in this two year clinical trial evaluating the efficacy and safety of an investigational intravenous drug for the treatment of ulcerative colitis. Study drug administration will occur each month by IV infusion and participants will be observed after drug administration. Subjects who respond well may proceed to an extension study with open label study drug during a maintenance phase. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

Patients with Crohn’s disease are eligible to participate in this two year clinical trial evaluating the efficacy and safety of an investigational intravenous drug for the treatment of Crohn's disease. Study drug administration will occur by IV infusion each month and participants will be observed after drug administration. Subjects who respond well may proceed to an extension study with open label study drug during a maintenance phase. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.